Comparative Pharmacology
Head-to-head clinical analysis: ANNOVERA versus HEATHER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANNOVERA versus HEATHER.
ANNOVERA vs HEATHER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing segesterone acetate, a progestin, and ethinyl estradiol, an estrogen. Segesterone acetate suppresses gonadotropin release, preventing ovulation; ethinyl estradiol contributes to contraceptive efficacy by stabilizing the endometrium and inhibiting gonadotropin secretion.
Heather is a combination hormonal contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Drospirenone, a spironolactone analog with anti-mineralocorticoid activity, also inhibits ovulation and may increase cervical mucus viscosity, impeding sperm penetration.
One vaginal ring inserted and left in place for 3 weeks, followed by a 1-week ring-free interval. Each ring releases ethinyl estradiol 0.024 mg/day and segesterone acetate 0.15 mg/day over 21 days.
5 mg orally once daily, increased to 10 mg after 2 weeks if tolerated; maximum 20 mg daily.
None Documented
None Documented
Terminal half-life of etonogestrel (ENG): ~25 hours; ethinylestradiol (EE): ~12 hours; steady-state achieved after 7-14 days.
Terminal elimination half-life: 4-6 hours. Clinical context: Requires every-6-hour dosing for steady state; therapeutic drug monitoring recommended in renal impairment.
Renal: ~60% as metabolites; fecal: ~35% as metabolites; biliary: minor.
Renal excretion of unchanged drug (60%) and hepatic metabolism with biliary/fecal elimination (40%).
Category C
Category C
Contraceptive
Contraceptive